Efficacy of OHSV-1-GM-CSF Combined with Anti PD-L1 Antibody on Bilateral Colon Xenograft Cancer Tumor of Mice
In order to verify the effectiveness of oHSV-1-GM-CSF combined with anti-PD-L1 antibody in treating bi-lateral colon cancer,a subcutaneous tumor model is set up using CT26.WT cells in BALB/c mice.Tumor-bearing mice are randomly assigned to four groups:Vehicle,oHSV-1-GM-CSF,anti-PD-L1,and oHSV-1-GM-CSF+anti-PD-L1.After administration,blood lymphocytes are taken from the mice and analyzed,and tumor regression or re-currence is also observed.The results show that oHSV-1-GM-CSF can express mGM-CSF on CT26.WT cells and there is no significant difference in oncolytic effect between oHSV-1-GM-CSF and the unload virus.In vivo experi-ments show that,oHSV-1-GM-CSF has a more substantial tumor inhibition effect than the no-load virus on the drug administration side,and oHSV-1-GM-CSF combined with anti-PD-L1 antibody produces a more substantial tumor inhibition effect on the whole body.The proportion of specific immune-related cells in peripheral blood and spleen of the combined treatment group significantly increases.Peripheral blood lymphocytes can kill CT26.WT cells in vitro,meanwhile has no effect on 4T1 cells of the same species.The combined treatment group significantly pro-longs the survival time of mice,with a survival rate of 33.3%,and tumor recurrence doesn't occur.In conclusion,the combination of oHSV-1-GM-CSF and anti-PD-L1 antibody can enhance the specific immunity of the body,pro-duce a lasting tumor inhibition effect,prolong the survival of mice,and provide data support for clinical treatment of colon cancer.
colon cancerbilateral colon cancer transplantation tumoroncolytic virusspecific immunity
万方数据
维普
